IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
========================================================================================================================================================================================

* Elisa A Rozeman
* Judith M Versluis
* Karolina Sikorska
* Esmée P Hoefsmit
* Petros Dimitriadis
* Disha Rao
* Ruben Lacroix
* Lindsay G Grijpink-Ongering
* Marta Lopez-Yurda
* Birthe C Heeres
* Bart A van de Wiel
* Claudie Flohil
* Aysegul Sari
* Stijn W T P J Heijmink
* Daan van den Broek
* Annegien Broeks
* Jan Willem B de Groot
* Marieke A Vollebergh
* Sofie Wilgenhof
* Johannes V van Thienen
* John B A G Haanen
* Christian U Blank